AUTHORS
Ariel Shaddaie, DO, Sarah Samorodnitsky, PhD2, Elisabetta Xue3, Roni Tamari, MD4, Gunjan L. Shah, MD, MS5, Brian C Shaffer, MD, MS6, Richard J. Lin, MD, PhD7, Esperanza Papadopoulos, MD8, Michael Scordo, MD9, Miguel-Angel Perales, MD10, Priscilla Baez, N/A11, Alyssa Kamrowski, MPH12, Tamanna Haque, MD13, Meira Yisraeli Salman14, Moneeza Walji, MD15, Doris M Ponce, MD16, Ann Jakubowski, PhD, MD17, Sergio Giralt, MD18
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Introduction:
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potential cure for high-risk myeloid malignancies. Despite modern advances, a substantial proportion of patients evaluated for allo-HCT ultimately do not proceed with this treatment. Factors contributing to this decision and the outcomes among those who are evaluated for, but who do not undergo allo-HCT remain poorly characterized. Prior institutional data demonstrated age-associated underutilization of allo-HCT, with only 33% of eligible patients with myelodysplastic syndrome (MDS) undergoing transplantation in 2018. Our current study aims to describe the clinical characteristics, reasons for not undergoing allo-HCT, and survival outcomes among patients with high-risk acute myeloid leukemia (AML) and MDS evaluated for allo-HCT who did and did not undergo allo-HCT.
Methods:
We performed a retrospective cohort study of adult patients with high-risk AML or MDS who underwent a formal multidisciplinary committee evaluation for allo-HCT between 2022 - 2024 at Memorial Sloan Kettering (MSK). Patients were categorized according to whether they subsequently underwent allo-HCT. Manual chart review collected baseline demographic, disease-related, and HCT-related variables, including age, diagnosis, disease risk classification, disease status at HCT evaluation, cytogenetic and molecular features, performance status, and comorbidity burden. They were compared between patients who did and did not proceed with allo-HCT using Wilcoxon rank-sum tests, Fisher’s exact tests, and Chi-squared tests. Non-mutually exclusive reasons for not proceeding with allo-HCT were also extracted. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier methods for AML and MDS patients separately from the date of HCT evaluation/consensus discussion.
Results:
A total of 293 patients were included in this study. Among 104 patients with MDS, 59% proceeded to allo-HCT. Among 189 patients with AML, 70% proceeded to allo-HCT. Patients were balanced with respect to sex, insurance status, percentile income by zip code, and presence of extramedullary disease. Patients who proceeded to allo-HCT were younger (median age 63 vs 66; p=0.005) and differed by diagnosis (p=0.042) and initial treatment exposure (p<0.001). AML ELN risk category also differed between groups (p=0.025), with a greater proportion of intermediate-risk disease proceeding. Among the 99 patients who did not proceed to allo-HCT, the most common non-mutually exclusive reasons were medical comorbidities (37%), persistent disease (35%), clinical deterioration (20%), low-risk disease (18%), psychosocial barriers (lack of caregiver, active substance use, adherence) (13%), patient preference (12%), disease risk too high (6%), and death before planned allo-HCT (2%). From the time of consensus, patients who underwent allo-HCT showed significantly improved PFS compared with those who did not proceed (AML: 12-month PFS, 69% [95% CI, 61–77%] vs. 52% [95% CI, 37–74%], p<0.001; MDS: 12-month PFS, 77% [95% CI, 65–91%] vs. 66% [95% CI, 50–85%], p=0.007). Similarly, they showed significantly improved OS compared with those who did not proceed (AML: 12-month OS=86% [95% CI, 80-92%] vs. 42% [95% CI, 30-57%], p<0.001; MDS: 83% [95% CI, 75-93%] vs. 62% [95% CI, 49-78%] p=0.001).
Conclusion
Among patients with high-risk myeloid malignancies referred for evaluation at a large, tertiary academic HCT center, more than half of evaluated patients proceeded to allo-HCT, suggesting increased allo-HCT utilization compared to historical data. Socioeconomic factors (insurance, income) were not associated with receiving allo-HCT. Clinical characteristics, such as age, disease risk and persistent disease, treatment exposure, and comorbidity burden were the primary determinants of allo-HCT utilization. Psychosocial barriers (social support, substance use) and patient preference accounted for a substantial proportion of those who did not proceed to allo-HCT, representing potentially modifiable barriers. The superior OS and PFS among patients who proceeded to allo-HCT, while confounded by indication, highlight the importance of multidisciplinary transplant decision-making and support future efforts to develop more standardized approaches to optimize transplant candidacy.
DISCLOSURES
Ariel Shaddaie, DO: No relevant conflicts of interest to declare.